Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study.

Cancer Res Commun · 2026 · PMC13018779 · PMID 41747221

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

In the analysis of select additional genes related to lenvatinib, FGFR3 and FGFR4 gene expression showed a positive trend of association with achieving an objective response [AUC (95% CI), 0.59 (0.41–0.78) for FGFR3 ; 0.64 (0.48–0.80) for FGFR4 ; Supplementary Fig.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.